×
ARYx Therapeutics SG&A Expenses 2010-2010 | ARYX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
ARYx Therapeutics sg&a expenses from 2010 to 2010. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
View More
ARYx Therapeutics SG&A Expenses 2010-2010 | ARYX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
ARYx Therapeutics sg&a expenses from 2010 to 2010. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$180.5B
Regeneron Pharmaceuticals (REGN)
$126.8B
Vertex Pharmaceuticals (VRTX)
$123.3B
Gilead Sciences (GILD)
$104.5B
Bristol Myers Squibb (BMY)
$99.4B
CSL (CSLLY)
$97.5B
GSK (GSK)
$86.3B
Alnylam Pharmaceuticals (ALNY)
$35.5B
Argenex SE (ARGX)
$32.1B
Biogen (BIIB)
$29.3B
BioNTech SE (BNTX)
$26.8B
Moderna (MRNA)
$26.1B
Illumina (ILMN)
$21.4B
BeiGene (BGNE)
$19.3B
Genmab (GMAB)
$17.5B
BioMarin Pharmaceutical (BMRN)
$13.6B
Exact Sciences (EXAS)
$13.1B
Vaxcyte (PCVX)
$13.1B
Insmed (INSM)
$12.9B
Incyte (INCY)
$12.9B
Bio-Techne Corp (TECH)
$12.7B
Sarepta Therapeutics (SRPT)
$12.1B
QIAGEN (QGEN)
$10.4B
Legend Biotech (LEGN)
$9.3B
Bio-Rad Laboratories (BIO.B)
$9.1B
Ascendis Pharma (ASND)
$8.9B
Roivant Sciences (ROIV)
$8.8B
Repligen (RGEN)
$8.2B
Intra-Cellular Therapies (ITCI)
$8.1B
Exelixis (EXEL)
$7.7B